Ginkgo Bioworks Holdings, Inc.

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8601 ^USD	+10.60%		-0.55%	-49.11%

Apr. 16	Il Granaio delle Idee and Ginkgo Bioworks Announces Strategic Collaboration to Optimize Sourdough Strains for Bakery Products	CI
Apr. 11	Transcript : Ginkgo Bioworks Holdings, Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024

Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 29, 2024 at 05:03 pm EST

Ginkgo Bioworks Holdings, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 26.98 million compared to USD 53.26 million a year ago. Revenue was USD 34.76 million compared to USD 98.29 million a year ago.

Net loss was USD 211.69 million compared to USD 175.47 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.1 a year ago.

Latest news about Ginkgo Bioworks Holdings, Inc.

Il Granaio delle Idee and Ginkgo Bioworks Announces Strategic Collaboration to Optimize Sourdough Strains for Bakery Products	Apr. 16	CI
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024	Apr. 11
Ginkgo Bioworks Acquires AgBiome's Platform Assets	Apr. 11	MT
Ginkgo Bioworks Expands Research Partnership With Novo Nordisk	Apr. 10	MT
Ginkgo Bioworks Partners With IdeeLab Biotechnology in Brazil	Apr. 08	MT
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service	Apr. 08	CI
Ginkgo Bioworks, Prozomix Collaborate on Enzyme Development	Apr. 03	MT
Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing	Apr. 03	CI
Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics.	Apr. 01	CI
Ginkgo Bioworks Awarded $6 Million DARPA Contract to Work on Cold-Weather Applications for Military and Commercial Use	Mar. 28	MT
Ginkgo Bioworks Wins DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments	Mar. 28	CI
Ginkgo Bioworks, AQUA Cultured Foods to Support Fish-Free Seafood Production	Mar. 27	MT
AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production	Mar. 27	CI
Ginkgo Bioworks, Imagindairy to Develop Animal-Free Dairy Proteins	Mar. 26	MT
Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins	Mar. 26	CI
Ginkgo Bioworks Collaborating With Dutch Biotech ProteoNic to Extend Proteins Production, Genetic Therapies	Mar. 13	MT
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05
TD Cowen Cuts Price Target on Ginkgo Bioworks to $3 From $7, Maintains Outperform Rating	Mar. 01	MT
Transcript : Ginkgo Bioworks Holdings, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Ginkgo Bioworks Q4 Loss Widens, Revenue Declines; 2024 Revenue Guidance Set; Shares Slump After Hours	Feb. 29	MT
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Ginkgo Bioworks Holdings, Inc. Provides Revenue Guidance for the Year 2024	Feb. 29	CI
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q4 Revenue $35M	Feb. 29	MT
Ginkgo Bioworks Acquires Reverie Labs, Proof Diagnostics, Patch Biosciences	Feb. 28	MT

Chart Ginkgo Bioworks Holdings, Inc.

Duration

Period

More charts

Company Profile

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ginkgo Bioworks Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.8601 USD

Average target price

1.92 USD

Spread / Average Target

+123.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GINKGO BIOWORKS HOLDINGS, INC.	-49.11%	1.72B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research